Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

Graft vs Host Disease Clinical Trial

Official title:

Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00574470
• Other study ID #: 200511718
• Status: Completed
• Phase: Phase 4
• First received: December 14, 2007
• Last updated: February 16, 2017
• Start date: January 2006
• Est. completion date: August 2008

Study information

• Verified date: February 2017
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see whether serious graft versus host disease which is not well controlled with steroid treatment can be controlled with therapy with both daclizumab and infliximab. We hypothesize that a combination of daclizumab and infliximab will more effectively treat graft versus host disease than therapy with a single drug. The study also looks at whether chronic graft versus host disease develops, and survival at 6 and 9 months post-treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 3
• Est. completion date: August 2008
• Est. primary completion date: November 2007
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of steroid refractory aGVHD defined as no response to methylprednisolone at 2 mg/kg for 1 week or disease progression after 72 hours of methylprednisolone at this dose. Potential subject will have had no decrease in any GVHD organ staging as follows:

• Skin rash, if present, does not decrease by one stage. This is based on the percent of the body involved with rash, plus presence of bullae and desquamation.

• Gut GVHD, if present, does not decrease by one stage. This is based on volume of diarrhea, pain, and ileus.

• Upper gastrointestinal GVHD, if present, does not resolve.

• Liver GVHD, if present, does not decrease by one stage. This is based on total bilirubin level.

• Prior allogeneic hematopoietic stem cell transplantation using bone marrow, peripheral blood or umbilical cord cells. Recipients of standard as well as nonmyeloablative transplants are eligible.

• No previous immune suppressive therapy given for treatment of acute GVHD except for corticosteroids.

• Absolute neutrophil count greater than 0.5x106/L.

• Estimated creatinine clearance greater than 30 mL/minute.

• Written informed consent

Exclusion Criteria:

• Patient receiving either infliximab or daclizumab within seven days of study.

• Patient with uncontrolled infections will be excluded.

• Patients receiving other investigational agents for GVHD prophylaxis or treatment.

• Patients with congestive heart failure.

• Patients with history of intolerance/ hypersensitivity to daclizumab or infliximab.

• Age less than 18 years.

• Patients who are pregnant or at risk of pregnancy and unwilling to use acceptable birth control methods.

• Patients with an allergy to murine products.

Related Conditions & MeSH terms

• Graft vs Host Disease

Intervention

Drug:
• daclizumab, infliximab
Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.

Locations

Country	Name	City	State
United States	University of Iowa Hospitals	Iowa City	Iowa

Sponsors (1)

Lead Sponsor	Collaborator
University of Iowa

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete or partial response of GVHD to treatment according to standard staging/grading scale		28 days
Secondary	incidence of chronic GVHD and overall survival		9 months